News
Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of ...
Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements ...
The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...
I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, ...
Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...
Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of ...
Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their ...
Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...
Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the ...
Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...
After 30 years with breast cancer, I urge others to pause, reflect and choose care based on long-term wellbeing, not fear or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results